» Articles » PMID: 14654547

P73 Expression in Human Normal and Tumor Tissues: Loss of P73alpha Expression is Associated with Tumor Progression in Bladder Cancer

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2003 Dec 5
PMID 14654547
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To characterize the expression profile of p73 in human normal tissues by immunohistochemistry (IHC) and to analyze the correlation between p73 expression and bladder cancer progression.

Experimental Design: CJDp73 was characterized for p73alpha detection in Western blot and IHC through its application to isoform-transfected 293 cells. Normal tissues were analyzed by IHC with the CJDp73 antiserum. Transitional cell carcinoma (TCC)-derived cell lines were subjected to reverse transcription-PCR and Western blot. TCC tissue microarrays were analyzed for p73alpha expression by IHC, and the results were statistically analyzed.

Results: p73 immunostaining was nuclear and restricted to epithelial cells of certain organs such as squamous epithelium of the epidermis and transitional epithelium of the bladder. The expression was also observed in certain specialized glandular epithelia such as acinar cells of breast and parotid gland. Four of seven TCC-derived cell lines had low to undetectable p73alpha protein levels. We found undetectable or low p73alpha expression in 104 of 154 (68%) TCC cases, this phenotype being more frequently observed in invasive tumors when compared with superficial lesions. This association was statistically significant (P < 0.0001). We also observed a significant association between p53, p63, and p73alpha alterations with bladder cancer progression (P < 0.0001).

Conclusions: p73alpha plays a tumor suppressor role in bladder cancer, and its inactivation occurs through an epigenetic mechanism, most probably involving protein degradation.

Citing Articles

TAp73 and ΔTAp73 isoforms show cell-type specific distributions and alterations in cancer.

Hrabal V, Stenckova M, Zavadil Kokas F, Muller P, Nenutil R, Vojtesek B Sci Rep. 2024; 14(1):29949.

PMID: 39622910 PMC: 11612387. DOI: 10.1038/s41598-024-80927-9.


Association of autosomal mosaic chromosomal alterations with risk of bladder cancer in Chinese adults: a prospective cohort study.

Song M, Han Y, Zhao Y, Lv J, Yu C, Pei P Cell Death Dis. 2024; 15(9):706.

PMID: 39349436 PMC: 11443067. DOI: 10.1038/s41419-024-07087-6.


Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives.

Liu S, Chen X, Lin T J Adv Res. 2022; 39:187-202.

PMID: 35777908 PMC: 9263750. DOI: 10.1016/j.jare.2021.11.010.


Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle-invasive bladder cancer.

Burgess E, Livasy C, Trufan S, Zhu J, OConnor H, Hartman A Mol Clin Oncol. 2022; 16(5):102.

PMID: 35463214 PMC: 9022081. DOI: 10.3892/mco.2022.2535.


Tissue-specific expression of p73 and p63 isoforms in human tissues.

Marshall C, Beeler J, Lehmann B, Gonzalez-Ericsson P, Sanchez V, Sanders M Cell Death Dis. 2021; 12(8):745.

PMID: 34315849 PMC: 8316356. DOI: 10.1038/s41419-021-04017-8.